The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia

1Shahid Beheshti University of Medical Sciences, Taleghani general Hospital & Study Group of Interferon in Iran (SG.IFN.IR), [email protected], Tehran, IR.Iran

2Shahid Beheshti University of Medical Sciences, Taleghani general Hospital & Study Group of Interferon in Iran (SG.IFN.IR), Tehran, IR.Iran

Hepatitis Monthly:Vol. 4, issue 7; 65-70

Published online:Sep 30, 2004

Article type:Research Article

How to Cite:Mirmomen S, Daryani N, Malekzadeh R, Zali M, Haghpanah B, et al. The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia. Hepat Mon. 2004;4(7):. doi:

Abstract

Background and aims: Interferon monotherapy is currently the only approved treatment for chronic hepatitis C (CHC) infection in transfusion dependent thalassemic patients, in whom ribavirin has limited use because of its hematologic complications. Our aim was to evaluate the efficacy and safety of pegylated Interferon monotherapy for the treatment of HCV infection in transfusion dependent thalassemic patients.

Methods: The trial was a multicenteric, open label, single treatment prospective study of Peginterferon alfa-2 a (PEGASYS, 180 micg per week) for a period of 48 weeks. 32 subjects, 18 to 42 years old (mean ± SD: 24.1 ± 9.44 years), whose serum HCV RNA was positive and mean ALT remained greater than 1.5 times upper limit of normal were enrolled. A percutaneous liver biopsy was performed before treatment and all patients underwent monthly assessment of any adverse events and were monitored for serum ALT. Efficacy was assessed by measuring serum HCV RNA following 24 week treatment-free period . One patient missed follow up and another died due to a drug unrelated cause and 30 patients were evaluated.

Results: Liver biopsy showed mild fibrosis in 31.2%, moderate fibrosis in 53.1% and cirrhosis in 15.6% of patients. Siderosis was severe in 16 patients (50%). In 26 out of 30 patients (86.6%) HCV RNA was negative at the end of treatment (ETR response). Data about 24 weeks post treatment was available in 23 patients, which showed a sustained virological response (SVR) of about 14/23 (60.8%). Two patients had an elevated end of treatment serum ALT instead of negative HCV RNA but their ALT returned to normal as soon as the treatment stopped. These 2 patients were considered to have INF toxicity.

Conclusion: Our experience indicates that the cure of HCV-related liver disease in thalassemic patients is not an unrealistic aim and may be reached with Peginterferon alfa-2 a monotherapy in a sizable portion of cases.

Keywords

Hepatitis C Virus - Thalassemia - Pegylated Interferon alfa-2a - Pegasys

Full Text

Full text is available in PDF

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy

Saleh Sandoughdaran,

Seyed Moayed Alavian,

Heidar Sharafi,

Bita Behnava,

Shima Salimi,

Leila Mehrnoush

,et al.

Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, et al. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy. Hepat Mon. 2015;15(1):e23564. doi: https://doi.org/10.5812/hepatmon.23564

20

Jan

2018

Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C

Simona Onali,

Ivana Maida,

Cinzia Balestrieri,

Francesco Arcadu,

Enrico Urru,

Davide Porcu

,et al.

Onali S, Maida I, Balestrieri C, Arcadu F, Urru E, et al. Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C. Hepat Mon. 2018;18(1):e61453. doi: https://doi.org/10.5812/hepatmon.61453

30

Sep

2004

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Nasser Ebrahimi Daryani,

Babak Haghpanah,

Ali Reza Sayyah,

Ali Asad Hashtroudi,

Mohammad Bashashati,

Parisa Poursamimi

,et al.

Daryani N, Haghpanah B, Sayyah A, Hashtroudi A, Bashashati M, et al. The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial. Hepat Mon. 2004;4(7):. doi:

30

Sep

2004

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Mohammad Reza Zali,

Hamid Mohaghegh Shalmani,

Mohsen Norouzinia,

Amir Hooshang MohammadAlizadeh,

Azita Nowroozi,

Negar Behrouz

Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C. Hepat Mon. 2004;4(7):. doi:

6

Mar

2016

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

Ehsan Aminizadeh,

Seyed Moayyed Alavian,

Ali Akbari Sari,

Nasser Ebrahimi Daryani,

Bita Behnava

Aminizadeh E, Alavian SM, Akbari Sari A, Ebrahimi Daryani N, Behnava B. Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials. Hepat Mon. 2016;16(3):e28537. doi: https://doi.org/10.5812/hepatmon.28537

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 2 weeks ago
Scopus by Title: 0
Last Update: 2 weeks ago
Scopus by Title (Ref): 0
Last Update: 2 weeks ago
CrossRef: 0
Last Update: 4 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Shahram Mirmomen:[PubMed][Scholar]
Naser Daryani:[PubMed][Scholar]
Reza Malekzadeh:[PubMed][Scholar]
Mohammad Zali:[PubMed][Scholar]
Babak Haghpanah:[PubMed][Scholar]
Parisa Poursamimi:[PubMed][Scholar]
Sayid Hashemi:[PubMed][Scholar]
Seyed Alavian:[PubMed][Scholar]

Official Journal of Research Center for Gastroenterology and Liver Diseases

Outlines

The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) monotherapy in the Treatment of Chronic Hepatitis C Infected Subjects with Transfusion Dependent Thalassemia

Abstract

Full Text

Similar Articles

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy

Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C

The Efficacy and Side Effects of Therapy with Peginterferon Alpha-2 a (PEGASYS) Combined with Ribavirin in Chronic Hepatitis C Patients: an open label Clinical Trial

Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials

Last Update: 2 weeks ago

Last Update: 2 weeks ago

Last Update: 2 weeks ago

Last Update: 4 days ago